Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exisulind, a selective apoptotic antineoplastic drug.

E T Goluboff1

  • 1Department of Urology and Comprehensive Cancer Center, School of Medicine, Columbia-Presbyterian Medical Center, New York, USA. eg45@columbia.edu

Expert Opinion on Investigational Drugs
|January 5, 2002
PubMed
Summary

Exisulind, a novel pro-apoptotic drug, effectively targets cancer cells by activating protein kinase G (PKG), leading to programmed cell death. Clinical studies show promise in preventing colorectal polyps and inhibiting prostate cancer progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

New approaches to the treatment of advanced prostate cancer.

Reviews in urology·2006
Same author

Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.

The Journal of urology·2001
Same author

Paternity in a patient with seminoma and carcinoma in situ in a solitary testis treated by partial orchidectomy.

BJU international·1999
Same author

A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells.

International journal of cancer·1999
Same author

Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995.

The Journal of urology·1999

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Exisulind is a novel targeted pro-apoptotic drug.
  • It selectively induces apoptosis in cancerous tissues via protein kinase G (PKG) activation.
  • This mechanism offers a new approach to cancer treatment.

Purpose of the Study:

  • To evaluate the antineoplastic effects of exisulind.
  • To assess its efficacy in preclinical cancer models and clinical trials.
  • To explore its potential as a monotherapy or in combination treatments.

Main Methods:

  • Preclinical studies in cancer cell lines and rodent models.
  • Clinical trials in patients with familial adenomatous polyposis (FAP) and prostate cancer.
  • Evaluation of exisulind's effect on tumor growth and specific biomarkers (e.g., PSA).

Related Experiment Videos

Main Results:

  • Exisulind demonstrated antineoplastic activity in various solid and hematological cancer cell lines.
  • It inhibited tumor growth in multiple rodent cancer models.
  • Clinical studies showed exisulind prevented colorectal polyp formation and slowed PSA progression in prostate cancer patients.

Conclusions:

  • Exisulind exhibits significant preclinical and early clinical antineoplastic activity.
  • Its pro-apoptotic mechanism and safety profile suggest broad therapeutic potential.
  • Exisulind may be effective as a monotherapy or in combination with chemotherapy and other targeted agents.